To order this 300+ page report, which features 140+ figuresand 125+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html
The USD 300 million (by 2030) financial opportunitywithin the microbiome contract manufacturing market has been analysed acrossthe following segments:
§ Type of ProductManufactured
§ Active PharmaceuticalIngredients (APIs)
§ Finish DrugFormulations (FDFs)
§ Type of Type ofFormulation
§ Solid Formulations
§ Oral Liquids
§ Injectables
§ Others
§ Scale of Operation
§ Clinical
§ Commercial
§ Company Size
§ Small-sized
§ Mid-sized
§ Large
§ Key GeographicalRegions
§ North America
§ Europe
§ Asia-Pacific and Restof the World
The LiveBiotherapeutic Products and Microbiome Contract Manufacturing Market, report features thefollowing companies, which we identified to be key players in this domain:
§ Bristol Myers Squibb
§ GlaxoSmithKline
§ Incyte
§ Novartis
§ Trillium Therapeutics
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Company Profiles
6. Regional Capability Analysis
7. Likely Partner Analysis
8. Clinical Trial Analysis
9. Capacity Analysis
10. Demand Analysis
11. Make versus Buy Decision Making Framework
12. Microbiome related initiatives of Big PharmaceuticalPlayers
13. Market Forecast
14. Conclusion
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
18. Appendix 3: List of Probiotic Supplement ContractManufacturers and
Microbial Contract Service Providers
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
